Santaolalla Aida, Hulsen Tim, Davis Jenson, Ahmed Hashim U, Moore Caroline M, Punwani Shonit, Attard Gert, McCartan Neil, Emberton Mark, Coolen Anthony, Van Hemelrijck Mieke
King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology Research (TOUR), London, United Kingdom.
Philips Research, Department of Hospital Services and Informatics, Eindhoven, Netherlands.
Front Artif Intell. 2021 Nov 16;4:769582. doi: 10.3389/frai.2021.769582. eCollection 2021.
Prostate cancer (PCa) is the most frequent cancer diagnosis in men worldwide. Our ability to identify those men whose cancer will decrease their lifespan and/or quality of life remains poor. The ReIMAGINE Consortium has been established to improve PCa diagnosis. MRI will likely become the future cornerstone of the risk-stratification process for men at risk of early prostate cancer. We will, for the first time, be able to combine the underlying molecular changes in PCa with the state-of-the-art imaging. ReIMAGINE Screening invites men for MRI and PSA evaluation. ReIMAGINE Risk includes men at risk of prostate cancer based on MRI, and includes biomarker testing. Baseline clinical information, genomics, blood, urine, fresh prostate tissue samples, digital pathology and radiomics data will be analysed. Data will be de-identified, stored with correlated mpMRI disease endotypes and linked with long term follow-up outcomes in an instance of the Philips Clinical Data Lake, consisting of cloud-based software. The ReIMAGINE platform includes application programming interfaces and a user interface that allows users to browse data, select cohorts, manage users and access rights, query data, and more. Connection to analytics tools such as Python allows statistical and stratification method pipelines to run profiling regression analyses. The ReIMAGINE Multimodal Warehouse comprises a unique data source for PCa research, to improve risk stratification for PCa and inform clinical practice. The de-identified dataset characterized by clinical, imaging, genomics and digital pathology PCa patient phenotypes will be a valuable resource for the scientific and medical community.
前列腺癌（PCa）是全球男性中最常被诊断出的癌症。我们识别那些癌症会缩短其寿命和/或降低生活质量的男性的能力仍然很差。为了改善前列腺癌的诊断，已经成立了ReIMAGINE联盟。磁共振成像（MRI）很可能会成为早期前列腺癌风险男性风险分层过程的未来基石。我们将首次能够将前列腺癌潜在的分子变化与最先进的成像技术相结合。ReIMAGINE筛查邀请男性进行MRI和前列腺特异性抗原（PSA）评估。ReIMAGINE风险评估纳入了基于MRI有前列腺癌风险的男性，并包括生物标志物检测。将对基线临床信息、基因组学、血液、尿液、新鲜前列腺组织样本、数字病理学和放射组学数据进行分析。数据将被去识别化，与相关的多参数磁共振成像（mpMRI）疾病内型一起存储，并与飞利浦临床数据湖（由基于云的软件组成）中的长期随访结果相链接。ReIMAGINE平台包括应用程序编程接口和用户界面，允许用户浏览数据、选择队列、管理用户和访问权限、查询数据等。与Python等分析工具的连接允许统计和分层方法管道运行剖析回归分析。ReIMAGINE多模态仓库为前列腺癌研究提供了一个独特的数据源，以改善前列腺癌的风险分层并为临床实践提供信息。以临床、成像、基因组学和数字病理学前列腺癌患者表型为特征的去识别化数据集将成为科学界和医学界的宝贵资源。
